P. Zintl

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

M. Zucchetti, F. D. De Braud, C. Sessa, 2009, European journal of cancer.

Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.

B. Monk, S. Kaye, C. Lebedinsky, 2011, Gynecologic oncology.

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials

M. Gore, Y. Park, C. Sessa, 2013, Medical Oncology.

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

M. Hidalgo, M. Mita, A. Mita, 2009, Clinical Cancer Research.

Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer.

B. Monk, S. Kaye, T. Herzog, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Therapy: Clinical Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

M. Hidalgo, M. Mita, A. Mita, 2009 .